Get informed when a big investor buys or sells
+ Follow-86.40%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Zentalis Pharmaceuticals (ZNTL) currently reports a ROE of -86.4%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Zentalis Pharmaceuticals's ROE history and peer comparisons.
Zentalis Pharmaceuticals's ROE of -86.4% is lower than the Healthcare sector average of 13.1%. That is roughly 759.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Zentalis Pharmaceuticals's current -86.4% should be judged against Healthcare norms (sector average: 13.1%) and against ZNTL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -86.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Zentalis Pharmaceuticals, and consider following ZNTL for alerts when major investors trade the stock.
Zentalis Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -86.4% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZNTL with unrelated industries.